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Abstract
Hepatitis B virus (HBV) is one of the most common DNA viruses that can cause aggressive hepatitis, cirrhosis and
hepatocellular carcinoma. Although many people are persistently infected with HBV, the kinetics in serum levels of viral
loads and the host immune responses vary from person to person. HBV precore/core open reading frame (ORF) encoding
proteins, hepatitis B e antigen (HBeAg) and core antigen (HBcAg), are two indicators of active viral replication. The aim of
this study was to discover a variety of amino acid covariances in responses to viral kinetics, seroconversion and genotypes
during the course of HBV infection. A one year follow-up study was conducted with a total number of 1,694 clones from 23
HBeAg-positive chronic hepatitis B patients. Serum alanine aminotransferase, HBV DNA and HBeAg levels were measured
monthly as criteria for clustering patients into several different subgroups. Monthly derived multiple precore/core ORFs
were directly sequenced and translated into amino acid sequences. For each subgroup, time-dependent covariances were
identified from their time-varying sequences over the entire follow-up period. The fluctuating, wavering, HBeAg-
nonseroconversion and genotype C subgroups showed greater degrees of covariances than the stationary, declining,
HBeAg-seroconversion and genotype B. Referring to literature, mutation hotspots within our identified covariances were
associated with the infection process. Remarkably, hotspots were predominant in genotype C. Moreover, covariances were
also identified at early stage (spanning from baseline to a peak of serum HBV DNA) in order to determine the intersections
with aforementioned time-dependent covariances. Preserved covariances, namely representative covariances, of each
subgroup are visually presented using a tree-based structure. Our results suggested that identified covariances were
strongly associated with viral kinetics, seroconversion and genotypes. Moreover, representative covariances may benefit
clinicians to prescribe a suitable treatment for patients even if they have no obvious symptoms at the early stage of HBV
infection.
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Introduction
Chronic hepatitis B virus (HBV) infection has been considered
to be a high mortality disease worldwide. To date, over three
hundred million people have died from primary adverse outcomes
including cirrhosis and hepatocellular carcinoma (HCC), which is
one of the most common primary liver malignancy [1–3]. A large
number of observations showed that high levels of viral loads in
serum would profitably promote the progression of chronic
hepatitis B infection. Elevated serum HBV DNA can be regarded
as anindicator ofhuman cirrhosis [4], andindependently associated
with HCC [5]. Three widely accepted phases of chronic hepatitis B
infection have been identified based upon serum alanine amino-
transferase (ALT) activity, the presence of hepatitis B e antigen
(HBeAg) and HBV DNA level: (i) immune tolerant phase (ii)
immune active (clearance) phase, and (iii) inactive phase [6,7].
Although most people are persistently infected with HBV, the
kinetics in serum levels of viral loads and the host immune responses
vary from person to person. For instance, according to the levels of
serum viral loads, patients with stationary pattern maintained stable
HBV DNA levels with fluctuations of less than 1.5 log copies/ml,
whereas the remaining subjects belong to the fluctuating pattern,
which can be further separated into declining and wavering pattern
[8]. Previous computational studies on hepatitis-related viruses have
led to the development of mathematical approach to modeling the
viral kinetics [9–11]. In our previous study, we have also developed
a regression model to predict the probability of HBeAg-serocon-
version in patients with HBeAg-positive chronic hepatitis B [8].
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32553However, the viral kinetics in response to the host immune
responses has yet been elucidated completely.
Four overlapping open reading frames (ORFs) within the HBV
genomic sequence that can be translated to viral core proteins or
HBc particles, surface proteins, reverse transcriptase and HBx
[12]. Some studies have proven that the HBeAg and hepatitis B
core antigen (HBcAg) encoded by HBV precore/core ORF are
used clinically as indicators of HBV replication [13,14]. Precore/
core mutations of HBV genome may cause amino acid changes of
the resultant protein HBeAg or HBcAg. For example, two
classical mutations including G1896A and G1898A within
precore/core gene region would change amino acid W28Stop
and G29S respectively [15] and they are also highly related to the
hepatomas [16]. Specific mutations in the precore/core region of
HBV enable virus to escape the host immune system’s re-
cognition, such as cell-mediated and humoral immune attack
[17–20]. These mutations are subsequently related to the severity
of liver disease [1,12,21]. Besides, variant HBV genotypes (A to
H, according to geographic distribution) can also cause various
degrees of liver damage and viral persistence. It has been
reported that patients infected with HBV genotype B are
associated with earlier HBeAg-seroconversion [22], whereas the
genotype C has a higher risk of cirrhosis and HCC development
compared to the genotype B [23].
A potentially powerful analysis to differentiating clinical
outcomes of HBV infection at an early stage is dominant, allowing
patients to receive an effective treatment and a suitable antiviral
therapy. The clinical outcomes of viral infection are the effect of
the interaction of viruses and their hosts [20]. Referring to
literature, Hosono et al. had indicated 13 positions with high
mutation frequencies called mutation hotspots among 21 different
HBV precore/core amino acid sequences in hepatomas [16]. The
identified mutation hotspots have a pleiotropic effect on both
immune and humoral immune responses, and their results also
suggested that the mutation codon 159 appears to correlate very
well with the mutation at codon 126. Recently, a similar result
from the genome-wide amino acid analysis of hepatitis C virus
showing that the covariances, derived from the high probability of
interactions of amino acid residue pairs, are very different in
response and nonresponse to interferon-based therapy [24]. In the
past decade, the covariance analysis has been used to identify the
residue pairs directly interacting in protein 3-dimentional
structures [25], to examine the functionally important residues
in proteins [26], and to infer protein-protein interactions [27].
However, the analysis of covariance in viral proteins in response to
patient serological or virological course of infection has yet been
conducted. It seems as if the existence of certain diverse genetic
interactions may be regarded as clinical indicators during the
course of viral infection.
In this study, we investigated if certain variations of HBV
precore/core encoding 212 amino acids (the regions of precore
and core have 29 and 183, respectively) were associated with the
viral kinetics, seroconversion or genotypes in treatment-naı ¨ve
chronic B patients during a one-year follow-up. Notably,
covariance analysis does not take into consideration on temporal
component of our sequence data, and therefore it is not a suitable
method to be applied directly. The results of mining single-point
mutations [28] varied with time of each residue were identified
and then utilized to make the developed method available for the
time-varying sequences, leading to an increase in the precision of
hotspots identification; hence, the resultant time-dependent
covariances may permit indicators of serological and virological
outcomes of HBV-infected patients.
Methods
Ethics statement
This study was verified and qualified by the Institutional Review
Board of National Cheng Kung University Hospital from 1/17/
2011 to 7/31/2012 under contract number ‘‘ER-99-386’’. The
ethics committee specifically waived the need for informed consent
forms since the data were publicly obtained from an observational
study and analyzed anonymously.
Patients and study design
A one year follow-up study enrolling treatment-naive 23
patients with HBeAg-positive chronic B in genotype B (8 patients)
and C (15 patients) from National Cheng Kung University
Hospital was conducted. A serum ALT level of less than 10 times
of the upper limit of normal (ULN), HBV DNA level at least than
1 million copies/ml, bilirubin level of less than 2.5 times of ULN,
the detectable of hepatitis B surface antigen (HBsAg) for at least
the previous 6 months, and the detectable of HBeAg were
examined at the time of screening. If the patients were infected
by hepatitis C or D viruses, had inactive HBsAg, immunodefi-
ciency virus infection, autoimmune hepatitis, decompensated liver
disease, or treated with systemic antiviral therapy, immunomod-
ulators, cytotoxic agents or corticosteroids, they would be excluded
in this study.
All the patients received placebos and had regular follow-ups for
1 year. Serum ALT, bilirubin, and HBV DNA levels were
monthly checked for all enrolled patients. According to the time-
varying serum viral load, eligible patients were divided into two
major subgroups including stationary pattern (6 patients) and
fluctuating pattern (17 patients). Patients with stationary pattern
have a stable HBV DNA level with fluctuations of less than 1.5 log
copies/ml during this one year period. The patients with
fluctuating pattern could be further divided into declining pattern
(9 patients) and wavering (8 patients) pattern. The more detailed
subgrouping criteria could refer to our previous work [8]. The
variables of clinical course and outcome among patients
categorized by patterns of viral kinetics were shown in Table 1.
Alternatively, as with the same subgroup criteria presented in our
previous work [8], seventeen patients with fluctuating pattern also
could be categorized into two subgroups including HBeAg-
seroconversion (6 patients) and HBeAg-nonseroconversion (11
patients) based on the detectable antibody of HBeAg in serum
leading to a year-end decrease in the level of HBeAg. Although the
remaining 6 patients with stationary pattern also have undetect-
able antibodies, they were still not categorized into the subgroup of
HBeAg-nonseroconversion since they have continuously stable
serum viral loads and ALT during the follow-up. The variables of
clinical course and outcome among these patients were shown in
Table 2.
During the one-year follow-up period, multiple full-length HBV
precore/core ORFs were sequenced monthly via clone sequencing
from the all 23 qualified patients. These DNA sequences were
directly in-frame translated into sequences of amino acid using
ExPASy translation tool (http://au.expasy.org/tools/dna.html).
Eventually, a total number of 1,694 amino acid sequences were
conducted as the input data of this study. As stated in the previous
two paragraphs, for each subgroup, time-dependent covariance
analysis were conducted on their corresponding time-varying
sequences. Several distinct covariances were presented by four
different comparisons including the stationary versus fluctuating
patterns, declining versus wavering patterns, HBeAg-seroconver-
sion versus HBeAg-nonseroconversion, and genotype B versus
Precore/Core Covariances in HBeAg+ Patients
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introduced in a later paragraph.
PCR amplification of HBV precore/core ORF and
genotyping
The serum HBV DNA was extracted with a Viogene extraction
kit, and real-time PCR was then performed on a LightCycler
instrument (Roche Diagnostics Applied Science) using primers and
probes. The genotyping method was based on melting curve
analysis (MCA) with LightCycler hybridization probes [29]. The
PCR reaction was run in a total volume of 10 ml, containing 2.5 ml
of DNA template, 1 ml of LightCycler FastStart DNA Master
Hybridization Mixture (Taq DNA polymerase, PCR reaction
buffer, 10 mM MgCl2, and dNTP mixture) (Roche Diagnostics
Applied Science), 1.2 ml of 25 mM MgCl2, 0.075 mlo f2 0mM
each of the probes, and 0.5 mlo f5mM of each primer. The
amplification using set 1 (ACDG/BEF set) and set 2-1 (B/E/F set)
amplicons was performed as follows: initial hot start denaturation
at 95uC for 10 min, which was followed by 45 cycles of
denaturation at 95uC for 10 s, annealing at 53uC for 10 s, and
extension at 72uC for 15 s. The programmed temperature
transition rate was 20uC/s for denaturation/annealing and 3uC/
s for extension. Real-time PCR monitoring was achieved by
measuring the fluorescence at the end of the annealing phase for
Table 1. Variables of clinical course and outcome among patients categorized by patterns of viral kinetics.
Variables Stationary pattern Fluctuating pattern Declining pattern Wavering pattern
Number of patients 6 17 9 8
Sex (male:female) 2:4 13:4 6:3 7:1
Age (years) 36.1763.66 34.1269.51 34.11611.15 34.1368.03
Baseline bilirubin (6ULN) 0.660.24 0.7160.26 0.6460.17 0.7860.33
Baseline ALT (6ULN) 1.3260.45 4.1362.78*** 4.2862.45** 3.9763.27
Baseline HBV DNA (log copies/ml) 8.8260.21 7.7561.23** 7.9261.02* 7.5661.47*
Baseline necroinflammatory score 2.8361.33 7.7662.8*** 7.6763.35** 7.8862.23***
Baseline fibrosis score 0.1760.41 2.0661.2*** 1.8961.36** 2.2561.04***
Final bilirubin (6ULN) 0.5860.20 0.6760.26 0.5660.21 0.7860.27
Final ALT (6ULN) 1.9161.57 1.4461.48 0.9560.60 1.9961.99
Final HBV DNA (log copies/ml) 8.9160.47 5.5961.29*** 4.9161.14*** 6.3461.05***
Final necroinflammatory score 4.6761.97 5.8862.90 5.1162.62 6.8663.13
Final fibrosis score 0.6760.52 2.0661.44** 1.7861.48 2.4361.40*
Genotypes (B:C) 3:3 5:12 1:8 4:4
Abbreviations: HBeAg: Hepatitis B e antigen; ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus.
*: P,0.05 compared with the stationary pattern.
**: P,0.01 compared with the stationary pattern.
***: P,0.001 compared with the stationary pattern.
doi:10.1371/journal.pone.0032553.t001
Table 2. Variables of clinical course and outcome among patients categorized by HBeAg-seroconversion.
Variables Patients with seroconversion Patients without seroconversion P value
Number of patients 6 11 -
Sex (male:female) 5:1 8:3 0.622
Age (years) 30.67612.77 3667.21 0.377
Baseline Bilirubin (6ULN) 0.7660.1 0.6860.32 0.42
Baseline ALT (6ULN) 3.0462.19 4.7362.97 0.205
Baseline HBV DNA (log copies/ml) 7.5861.57 7.8461.07 0.722
Baseline Necroinflammatory score 6.3363.01 8.5562.46 0.159
Baseline Fibrosis score 1.561.22 2.3661.12 0.184
Final bilirubin (6ULN) 0.6860.15 0.6660.30 0.942
Final ALT (6ULN) 0.8560.33 1.7861.76 0.105
Final HBV DNA (log copies/ml) 4.8461.29 6.1561.09 0.009
Final necroinflammatory score 5.3363.39 6.162.56 0.731
Final fibrosis score 2.3361.51 1.9061.45 0.584
Genotypes (B:C) 3:3 2:9 0.169
Abbreviations: HBeAg: Hepatitis B e antigen; ALT: Alanine aminotransferase; ULN: Upper limit of normal; HBV: Hepatitis B virus.
doi:10.1371/journal.pone.0032553.t002
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the reaction at 95uC for 10 s and then lowering the temperature to
48uC at a transition rate of 20uC/s and holding for 60 s. It was
then followed by heating slowly at a transition rate of 0.1uC/s to
80uC with continuous collection of fluorescence at 640 nm. The
melting curve and quantitative analysis were conducted by using
LightCycler analysis software version 3.5 following the manufac-
turer’s instructions (Roche Diagnostics Applied Science). For set 2-
2 amplicon (A/CD/G set+C/D set), the PCR reaction was the
same as that of set 1 and set 2-1, except for the extension at 72uC
for 20 s.
Cloning process
HBV DNA was amplified by PCR with commercially available
Herculase enhanced DNA polymerase (Stratagene). Primers amplify
the precore/core ORF of the HBV strains. The cycling conditions
of PCR were 3 minutes at 94uC followed by 35 cycles of
40 seconds at 94uC, 50 seconds at 60uC and 1 minute at 72uC.
The PCR products were separated by 1% agarose gel electropho-
resis and purified for sequence analysis using the QIAGEN QIA
Quick Gel Extraction Kit. Purified PCR products were cloned into
a pGEM plasmid and then analyzed by sequencing of 20 clones
using the Applied Biosystems ABI PRISM Big Dye Terminator
Cycle Sequencing Ready Reaction Kit. An automated DNA
sequencer ABI 310 was used to determine amplified DNA
sequences.
Time-dependent covariances identification
Time-dependent covariances can be generated by two compu-
tational steps. For each subgroup, covariance analysis is firstly
applied on the patients’ corresponding time-varying HBV
precore/core amino acid sequences. Then the identified covari-
ances will be filtered by mining single-point mutations of each
residue that do not vary with time. The remaining set containing
covariances from the filtering process was called ‘‘time-dependent
covariances’’.
The following equations below show you how to identify the
covarying pairs of residues.
S~
P L
1
Nobs{Nexp
   2
Nvalid
ð1Þ
In Eq. (1), S represents the degree of covariance between two
columns (positions) in a set of aligned amino acid sequences. L is
the list number of all observed pairs and Nobs is the number of
occurrences for the pair of residues. The expected number, Nexp,
for the pair as shown in Eq. (2).
Nexp~
CxiCyj
Nvalid
ð2Þ
In Eq. (2), Nvalid is the number of sequences within a sequence
set, Cxi is the observed number of residues x at position i, and Cyj is
the observed number of residues y at position j. For example, given
that a patient subgroup has only 4 (Nvalid=4) aligned sequences
having 5 amino acids at two different time points, t1={LNVIV
and IYVLG} and t2={IYVLG and VYVLG}. The covariance of
position 1 (x=1) and 5 (y=5) can be calculated by the following
steps: Since covariance analysis is only available on handling a
general set of sequences, i.e., without considering the order of
sequences being analyzed, the input sequences are subsequently
put together as a new set, {LNVIV, IYVLG, IYVLG and
VYVLG}. Position 1 has three distinct amino acids, L (C1L=1), I
(C1I=2) and V (C1V=1), and position 5 has two, V (C5V=1) and G
(C5G=3). From combinational pairing of these two positions, six
(L=6) observation pairs including LV, LG, IV, IG, VV and VG
can be generated. Mapping onto the original 4 sequences, IG
appears twice, LV and VG appear once, and LG, IV and VV do
not appear at all. Thus, score S of these two positions is about 0.44.
The detailed computational process is given by the following
formula.
S~
2{ 2|3
4
   2z 1{ 1|1
4
   2z 1{ 1|3
4
   2z 0{ 1|3
4
   2z 0{ 2|1
4
   2z 0{ 1|1
4
   2
4
~0:44
After iteratively calculating covariance scores of all possible
residue pairs, a user-set threshold can be used to judge whether
there truly exists covariance of a residue pair. In this study, the
threshold was set as 0.5. For each pair, if its score below 0.5, there
does not exist a covariance. However, how to set an appropriate
threshold is a challenge. Two statistical methods were used to
examine it as shown in the part of Statistical analysis.
The identified covariances were further filtered by the results of
single-point mutations to derive time-dependent covariances. An
example of mining single-point mutations was shown in Figure S1.
Given that a patient subgroup has 5 equal-length sequences at
each time point, spanning from t1 to t4. Conserved sequences, CS1
to CS4, of each time point will be subsequently identified. For each
position, residues with different amino acids at two consecutive
time points will be mined. From looking at the mining results listed
at the bottom of the figure, ‘‘4: t1 (D)Rt2 (H)’’ represnts that a
residue with D turns into H at position 4 from t1 to t2. The same
concept can be applied on the remaining rules. Finally, if residues
covary in the identified covariances via Eq. (1) and (2) as well as do
not appear in the list of point-mutation rules (these residues do not
change over time), it will be eliminated from the first step-derived
covariances. In other words, the preserved residues not only have
covarying characteristics but also alter the properties of amino
aicds over time. These filtered covariances were called ‘‘time-
dependent covariances’’.
Leave-one-out-like cross-validation
Representative covariances of each subgroup were examined by
using a proposed leave-one-out-like cross-validation method. An
example showed in Figure S2 illustrates how to perform the
evaluation process. Given that a patient subgroup involves 3
patients. The sequences derived from each one of the patients will
be regarded as the testing data, and the remaining subjects are
belonging to the training data. The covariances can be identified
through a complete analysis flow showed in Figure 1. If
covariances of testing data are covered by that of its corresponding
training data, the covariances will be preserved as shown at the
bottom of the figure. In this example, there are 2 patients can be
covered by covariance 116–126 and 126–159; thus its coverage
rate is about 67% (2/3).
Statistical analysis
In Table 1 and Table 2, the frequencies and distributions of
categorical variables for all patients were compared by Chi-square
test. Continuous variables were compared by Student’s t-test.
For determining an appropriate threshold of covariance
analysis, we set same, 0.5, as a previous work by Aurora et al.
[24]. In Table S1, two statistical examinations including
Precore/Core Covariances in HBeAg+ Patients
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significance of identified covariances of each patient subgroup.
Thirteen mutation hotspots of HBV precore/core amino acids in
hepatomas proven by Hosono et al. [16] were curated as a ground
truth. These hotspots were listed in Text S1. McNemar’s test was
utilized to confirm whether distributions and frequencies of
categorical variables (hotspots) are associated with covariances. Then
permutation test was used to examine whether ratios of hotspots to
covarying residues are larger than a random condition. In brief, we
defined Rhotspots/residues|covariances as a ratio of the number of hotspots
to all covarying residues, and Rhotspots/residues|random as a random
distribution ratio of the number of hotspots to a full-length, 212
residues, HBV precore/core amino acid sequence. A null hypothesis
Rhotspots/residues|random.=R hotspots/residues|covariances by performing
1,000 resampling was tested. Permutation test P value is the
proportion of these resamples that give a result the null hypothesis
is true. The results are considered statistically significant as long as
P,0.05 from any one of two tests.
Results
An overview of data step processing
Monthly derived multiple HBV precore/core amino acid
sequences of each patient were prepared as input data for mining
covariance and single-point mutation rule. A schematic overview of
the study was shown in Figure 1. Covariances of each subgroup
could be derived by applying covariance analysis directly on their
corresponding sequences such as a whole period (middle left in
Figure 1) and an early stage (middle right in Figure 1). The
covariances were visually presented in a network, in which the
nodes represented covarying amino acid residues. If there is a
covariance of two residues, they will be linked by an edge.
Literature-reported mutation hotspots were shown in red, whereas
the remaining nodes were shown in blue. Then the single-point
mutations would be mined from the time-varying sequences. A
simple list of point mutation rules has been shown in the middle of
the figure. Each rule consisted of position number of residues and
one-letter codes of amino acids at two time points. Twenty kinds of
amino acids weredivided into4 subgroups based on their side-chain
properties including non-polarity (G, A, V, L, I, F, W, M and P),
neutrality (Y, N, Q, S, T and C), acidity (D and E) and alkalinity (H,
K and R). The rules would be marked in bold if their changes
involve two different properties. Only bold mutation rules will
subsequently be used to screen the aforementioned whole period
covariances, namely time-dependent covariances. Diverse time-
dependent covariances of each subgroup may provide insights into
residue interactions in responses to serum viral kinetics, serocon-
version and genotypes during the course of HBV infection.
Figure 1. Schematic overview of data step processing. Data processing flowchart is composed of four steps from top to bottom. First, the
input data is one subgroup corresponding set of HBV time-varying amino acid sequences. Second, whole period covariances, early stage covariances
and single-point mutations varied with time are identified as shown in the middle part of the figure. Third, through filtering whole period covariances
with single-point mutation rules, time-dependent covariances can be derived. Finally, representative covariances of each subgroup can be generated
via determining the intersection of time-dependent and early stage covariances. t1,t p,t n and t12 stand for time points at baseline, peak, nadir and
year-end viral loads respectively.
doi:10.1371/journal.pone.0032553.g001
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good diagnosis or a suitable treatment at an early stage of HBV
infection even if they exhibit no obvious symptoms. Hence, for
each subgroup, covariances at an early stage spanning from
baseline, t1, to a peak of viral load, tp, were used to determine the
intersections with their corresponding time-dependent covarianc-
es. These preserved covariances are shown in the bottom right of
Figure 1. In this study, a proposed leave-one-out-like cross-
validation was used to develop the representative covariances of
each subgroup that visually present in a tree-based structure. It
may help clinicians to predict the serological or clinical outcomes
at an early stage of HBV infection.
An improvement to increase the proportion of mutation
hotspots
To check whether covariances derived from HBV precore/core
amino acid sequences are associated with serum viral kinetics,
seroconversion and genotypes, Figure 2 presents three kinds of
covariances of each subgroup, including whole period covariances
(left column), time-dependent covariances (right column) and time-
dependent covariances regardless of amino acid properties (middle
column). All of the single-point mutations to time-dependent
covariances were shown in Table S2 and the detailed rules in
Table S3. Moreover, consulting previously identified HBV
infection-related mutation hotspots in hepatomas [16], 13 residues
(Text S1) were curated to observe hotspot distributions in our
results. Intriguingly, most subgroups showed higher proportions of
mutation hotspots filled in red that was remarkable in the time-
dependent covariances compared to the other two (left and middle
column).
In addition, the average number of degrees of every position
(node) was calculated from 8 covariance networks involved in the
same column in order to achieve an objective comparison of the
covariances displayed in Figure 2. The average degree of each
amino acid position showed a similar trend in Figure 3. For
instance, in Figure 3C, seven out of seventeen covarying residues
were marked with asterisks, and its hotspot proportion is about
0.412 (7/17) which is greater than the others 0.235 (8/34)
(Figure 3A) and 0.320 (8/25) (Figure 3B). Thus, our results
suggested that high rates of mutations were most likely to be found
via integration process of covariance analysis and single-point
mutations discovery compared with only using covariance analysis.
Following the comparison, the identified residues with time-
dependent covariances may play important roles during the course
of HBV infection.
Informative covariances correspond to clinical signatures
Plenty of studies from clinical or epidemiological researches on
HBV investigation have claimed that specific amino acid
mutations, especially in the regions of immunocyte epitopes, of
HBV precore/core ORF encoding proteins would encompass the
activities of cellular immune responses, such as B cell, T helper
and cytotoxic T lymphocyte activations, for HBV DNA clearance
in some liver-related diseases [12,20,30,31]. However, these
identified mutations were not derived from an analysis of massive
time-varying sequences even if several publicly acceptable
mutation hotspots had been reported. Hence, we had an insight
into our identified time-dependent covariances and made some
comparisons for four matched pairs of each case-control subgroup,
such as the stationary pattern versus fluctuating pattern, declining
pattern versus wavering pattern, HBeAg-seroconversion pattern
versus HBeAg-nonseroconversion pattern and genotype B versus
genotype C. Interestingly, in each pair comparison, the latter
always have more complicated covariances stemming from more
nodes and edges compared to the former. For example, the size
(33) of fluctuating pattern time-dependent covariances is bigger
than that of stationary pattern (3) (as shown in Figure 2). This
result is certainly reliable because patients with stationary pattern
have a stable serum HBV DNA level. Accordingly, HBV precore/
core ORFs encoding proteins, HBeAg and HBcAg, were much
easier to be recognized by the host’s immune system [32]. In
addition, the sizes of covariances are also correlated with the
genotypes as well as HBeAg-seroconversion. It also has been
reported that HBV infected patients in genotype C have a late
HBeAg-seroconversion and more severe liver fibrosis compared to
the genotype B [22,33]. This consistent result indicated that the
time-dependent covariances may not only contribute to serological
outcomes but also play a functional role in the process of HBeAg-
seroconversion [22]. Thus, our results corresponded to the
previous studies and suggested that the complexity of covariances
was strongly associated with viral kinetics, HBeAg-seroconversion
and genotypes. To the best of our knowledge, these covariances for
each subgroup have yet been reported. It may have some
biological insights into a clinical enigma.
HBV genotype C infections accompanied with a cyclic
process of point mutation
In prior sections, our results have indicated that the various
covariances were strongly associated with the patterns of viral
kinetics, seroconversion and genotypes. This phenomenon was
predominant in the time-dependent covariances, i.e. the residues
have substitutions with different amino acid properties over time.
Recently, some studies claimed that patients infected with HBV
genotype B have a higher probability for HBeAg-seroconversion at
an early stage compared to genotype C [22,34,35]. HBV genotype
B could also cause a less progressive liver disease [34,36]. Thus,
different HBV genotypes would contribute to the outcomes of
liver-related disease and virus persistence in the hosts. Here a
question was raised whether the substitutions occur frequently in
the patients with genotype B or C. Patients involved in the same
subgroup were separated into two cohorts based on their HBV
genotypes, B or C. We made the reasonable assumptions that
HBV have a high activity in the early viral infection because at
that time the viral foreign antigens have yet been recognized or
even have yet been eliminated by host immune systems. Hence,
for a given point mutation rule to one residue position, if a
substitution (e.g., HRany kind of amino acids) took place at the
baseline of the one year period and ultimately reversed to the
original type of amino acid (e.g., any kind of amino acidsRH)
before the year-end time point period regardless of what kind of
amino acids appeared during the intermediate steps, it was called
‘‘cyclic process’’, whereas it was called ‘‘acyclic process’’.
According to this definition, the point mutations showed in
column ‘‘Single-point mutations with different amino acid
properties’’ in Table S2 that could be partitioned into several
parts as shown in Table 3 and Table 4. It was obvious that the
cyclic processes were predominant in the genotype C compared to
B. Moreover, the genotype C also has a high proportion of
mutation hotspots in cyclic processes (Table 3). For example, in
the subgroup with wavering pattern, there were three hotspots out
of seven single-point mutations (3/7) in cyclic process that was
certainly higher than its corresponding control, genotype B (0/3).
However, this phenomenon could not be observed in acyclic
processes (Table 4). Taken together, our results suggested that
biological alterations in precore/core amino acids of HBV
genotype C have a higher complexity than that of genotype B.
These results were consistent with previous studies. The identified
single-point mutations with a cyclic process may also play
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reported.
Development of a tree-based visualization for an early
prediction
According to the virological and serological patterns stated in
the section of patients and study design, a HBV infected patient
can be categorized into stationary or fluctuating patterns followed
by declininig, wavering, HbeAg-seroconversion or HbeAg-non-
seroconversion patterns. However, patients undergo early phar-
maceutical interventions which can mitigate unwanted clinical
symptoms and prolong the duration of chronic active liver disease.
Thus, a potentially powerful prediction at early HBV infection is
required.
In this section, we introduced another approach on an attempt
to predict the serological or virological outcomes at an early stage
of HBV infection. Covariance analysis was applied on the
sequences derived from the early stage spanning from baseline,
t1, to maximal serum HBV DNA time point preceding the nadir,
tp, (middle right in Figure 1). The identified early-stage
covariances were subsequently used to determine the intersections
with aforementioned time-dependent covariances (bottom left in
Figure 1). All the processes followed the principle of our proposed
leave-one-out-like cross-validation – see also Methods. For
increasing the feasibility of our results to clinical application,
displaying data in a readily comprehensible fashion to clinicians is
required. The representative covariances of each subgroup in this
study were utilized to develop a tree-based visualization flow in
Figure 4. Most subgroups have more than half coverage rates. This
flow may provide a useful information to clinicians and it is also a
simple application on the clinical diagnosis to predicting what kind
of patterns for patients who will be exhibited at the terminal stage.
For example, when a new HBV-infected patient comes to a
hospital, a covariance analysis will be applied on their amino acid
sequences. Then the resultant covariances will be checked whether
they are covered by any possible covariances from top to bottom of
the tree. Clinicians can prescibe the patient a suitable treatment
for avoiding the development of an aggressive liver disease. On the
other hand, it is worth noting that both HBeAg-seroconversion
and HbeAg-nonseroconversion subgroups had an identical
Figure 2. Comparisons of covariances in all subgroups. Left column shows the covariances derived from a set of whole period sequences. The
time-dependent covariances are shown in the middle and right columns.
X: Residues changed with time regardless of amino acid properties. P:
Proportion of mutation hotspots of covariances. *: Proportion of mutation hotspots greater than left column. **: Proportion of mutation hotspots
greater than middle column.
doi:10.1371/journal.pone.0032553.g002
Figure 3. Average degrees of each position of three kinds of covariances identification method. X-axis represents amino acid positions
of a full length of HBV precore/core amino acid sequences. Y-axis represents average numbers of degrees. A) Average degrees of positions of whole
period covariances. B) Average degrees of positions of time-dependent covariances regardless amino acid properties. C) Average degrees of positions
of time-dependent covariances. *: Literature-reported mutation hotspots.
doi:10.1371/journal.pone.0032553.g003
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the characteristics of covarying pairs of amino acids, the pairs were
counted from both subgroups. The pair G-L and S-I were
predominant in HBeAg-seroconversion and HbeAg-nonserocon-
version respectively. A significant distribution was examined by
using Chi-square test (p,0.0001, data not shown). These two sites
not only had been identifed as hotspots but also could be
considered as a good biomarker of the two subgroups in early
HBV infeciton. Therefore, in this section, the interesting results
not only provided a potential clinical diagnosis prediction but also
showed several novel covariances of most subgroups.
Discussion
In this study, we utilized an integration of covariance analysis
and a mining single-point mutation method on a massive monthly
serum-derived HBV precore/core amino acid sequences to
identify several representative covariances of each subgroup with
various serological or virological patterns. This prospective study
has many advantages since we integrated statistical analyses,
computing techniques and large-scale viral sequences over a
yearlong observation period. This was different from previously
traditional approaches; clinical numeric data retrieved from
patient samples were easier to be analyzed by clinicians or
statisticians. However, to date, there are still many problems are
left unresolved due to high mutation rates of viruses. A lot of
information hidden in the viral sequences is also important to the
interplay between viruses and infected patients. For example,
which mutation residue of HBV precore/core amino acids is
mainly responsible for escaping attack from the host immune
system even if a small number of mutation hotspots have been
identified? This is the main reason we attempted to have insights
into the amino acid alterations affecting the outcomes of HBV-
infected patients in this work.
Since the replication of HBV DNA in human hosts is error-
prone [20], from a clinical point of view, clinicians cannot easily
predict or find out the exact amino acid mutations or underlying
mechanisms to the high diversity of clinical syndromes. Predicting
and/or discovering the specific single or multiple mutations
associated with the outcomes of HBV infection is a challenge [32].
An analytical approach to amino acid sequences is indispensable
to answer the question. In addition, it is well known that two
serum-derived proteins, HBeAg and HBcAg, not only can be
encoded by precore/core ORF but also have been regarded as two
main indicators of active HBV replication. The expressions of the
foreign antigens could be altered through a DNA transcriptional
regulation with cis- or trans-mechanisms. In the previous cases,
plenty of studies have reported that the consequences of mutations
in basal core promoter were associated with the liver disease and
risk of HCC development even after adjusting for HBV genotypes
Table 4. Single-point mutations with different amino acid properties in acyclic processes.
Subgroup types Number of patients
{ Genotype B Number of patients
{{ Genotype C
Stationary pattern 3 3
Fluctuating pattern 5 34*, 67*, 89*, 108,
116*, 122, 164, 197
12 10, 34*, 42*, 56, 70, 92, 106, 116*, 126*,
142, 145, 147, 159*, 160, 192, 209
Declining pattern 1 8 10, 34*, 42*, 56, 70, 92, 106, 116*, 126*,
142, 145, 147, 159*, 192, 209
Wavering pattern 4 34*, 67*, 89*, 108,
116*, 122, 164, 197
4 56, 92, 159*, 160
HBeAg-seroconversion 3 34*, 67*, 89*, 197 3 10, 34*, 42*, 70, 116*, 126*, 159*, 209
HBeAg-nonseroconversion 2 34*, 108, 116*,
122, 164
9 56, 92, 106, 116*, 126*, 142, 145, 147,
159*, 160, 162
HBeAg: Hepatitis B e antigen.
{: Number of patients in genotype B.
{{: Number of patients in genotype C.
*: Literature-reported mutation hotspots.
doi:10.1371/journal.pone.0032553.t004
Table 3. Single-point mutations with different amino acid properties in cyclic process.
Subgroup types Number of patients
{ Genotype B Number of patients
{{ Genotype C
Stationary pattern 3 34*, 104 3
Fluctuating pattern 5 5, 44, 94 12 29*, 55, 56, 64, 89*, 109, 110, 116*, 159*, 164, 182*
Declining pattern 1 8 55, 56, 89*, 116*, 159*, 164
Wavering pattern 4 5, 44, 94 4 29*, 64, 109, 110, 159*, 164, 182*
HBeAg-seroconversion 3 3 56, 89*, 116*
HBeAg-nonseroconversion 2 5, 44, 94 9 29*, 55, 64, 109, 110, 116*, 159*, 164, 182*
HBeAg: Hepatitis B e antigen.
{: Number of patients in genotype B.
{{: Number of patients in genotype C.
*: Literature-reported mutation hotspots.
doi:10.1371/journal.pone.0032553.t003
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influence HBV persistence; instead, it only focused on the protein
quantity alterations. Only a small proportion of studies focused on
the amino acid mutations of HBV precore/core or other ORF
[32,39,40]. It has been reported that 13 significant mutation
hotspots were located in MHC class II-restricted T cell epitopes in
host in hepatomas [16]. These hotspots were considered as a
ground truth for evaluating the identified covarying residues.
Figure 3C showed a higher hotspot precision compared to only
applying covariance analysis method as shown in Figure 3A. This
result indicated that our integration method may have more
chances to provide more biological insights into genetic regulations
of HBV. The covarying residues presented in Figure 3C were
covered by three well-known mutation clusters located on
precore/core region including regions 77–89, 113–130 and 176–
184 [41–43]. Specifically, an Asian study claimed that three most
frequent found hotspots including L89V, S116G and I126L were
responsible for HBV escaping immune response in Chinese with
chronic hepatitis B [44]. These hotspots also could be identified
by our integration method. In order to further verify if our results
are credible, the literature reports on three class II HLA restricted
T cell epitopes, spanning amino acids 29–49, 79–98 and 146–160,
within precore/core protein identified by Penna et al. [45] and
our findings including mutation position 34, 44, 89, 94 and 159
were congruent. Moreover, we also discovered several multiple
mutations 55, 56, 159 and 164, that were located on class I HLA
restricted T cell epitopes, spanning amino acids 47–56, 159–169
and 170–180, [46,47]. It is worth noting that three amino acid
positions 34, 55 and 94 within human HLA restricted T cell
epitopes have yet been reported. These mutations could be
regarded as substantial hotspots to the course of HBV infection.
Besides, there were also some putative mutations exhibited in our
results such as position 64, 70, 104 and 108, even if it have not
been regarded as main targets of immunocyte recognition. Taken
together, the mutations discovered by our proposed integration
method corresponded highly with antigen expression in the
context of cellular immune-recognized epitopes. These findings
may lead to a dramatically conformational change of HBeAg and/
or HBcAg structures during the period since covariance analysis
had been used to identify the residue pairs in protein 3-
dimentional structures [25,48].
Another important issue in epidemiology is the viral activities in
patient. Infections were often of high persistence due to highly
dynamic mutations in viral genomics or different genotypes [49].
In the latter case, HBV genotype B induced a greater T helper cell
1 response than T helper cell 2, compared to genotype C during
hepatitis flares in HBeAg-positive patients [35]. However, to date,
the underlying mechanisms have yet been elucidated completely.
In this prospective study, all samples and serum-derived HBV
precore/core ORFs were directly sequenced and translated into
amino acids from HBeAg-positive chronic B carriers. In our
previous work, we had presented a quick and useful method using
two-step melting curve analysis for genotyping of HBV genomic
sequences [29]. Different genotypes may associate with the certain
mutations through mining single-point mutation rules from time-
varying sequences; genotype C had an overwhelming majority of
cyclic processes. This interesting result hinted that the original
amino acids of HBV genotype C may have a higher probability of
reappearance. In other words, HBV genotype C has a higher
adaptability compared to the genotype B. Checking with the
previous literature, a large number of researches showed that the
genotypes of HBV were strongly associated with the chance of
Figure 4. A tree-based visualization flow. Each rectangular box represents the subgroups. Representative covariances are next to each box.
Numerator and denominator showed in parentheses indicate covered and intra-subgroup patient numbers respectively.
doi:10.1371/journal.pone.0032553.g004
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and patterns of viral kinetics [22,33,35,50,51]. For example, HBV
genotype C takes a more aggressive disease course than genotype
B in HBeAg-positive patients [50]. Our results corresponded
highly to the previous studies. In Table 3, the genotype C has a
larger number of cyclic mutations and literature-reported
mutation hotspots compared to B during this one year period,
we reasonably inferred that HBV genotype C has a higher ability
to escape the host immune system responses. Moreover, these
changes were accompanied with changes in amino acid properties,
which may lead a dramatically conformational change for the
protein structure(s). It is worth noting that the identified single-
point mutations have yet been reported, which may be novel
immunocyte recognition targets for developing targeted therapies
in the future.
This study has several advantages. We improved the drawback
of only using covariance analysis method via integrating additional
information, such as single-point mutation rules with different
amino acid properties from patient monthly serum-derived
sequences. Moreover, we developed a tree-based visualization
flow chart which could be regarded as a useful tool to predict the
serological or virological outcomes in an early HBV infection stage
(Figure 4). Interestingly, the coverage rate of subgroup with
stationary pattern is zero, whereas most remaining covariances
have more than half coverage rates. To the best of our knowledge,
stationary pattern have a serologically stable HBV DNA level due
to no specific mutation sites. Therefore, the tree-based visualiza-
tion flow chart is applicable to clinical diagnosis and is valuable for
clinicians to prescribe patients appropriate treatment before
symptomatic evidence appears. Our proposed method could be
widely applied on sequences of other species even if the sequence
length is not long.
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